Medikine, Inc

Medikine is a biopharmaceutical company with a mission to transform the discovery of oncology, autoimmune disorder, and infectious disease therapeutics by employing a disruptive and versatile drug discovery platform that generates modular “PEPTIKINES” that are smaller in molecular size than, and structurally unrelated to, the natural cytokine proteins they emulate. These PEPTIKINES are readily amenable to further enhancement for desired pharmacokinetics or added pharmacologic features. Medikine’s lead product candidate MDK-703, which is planned to enter clinical trials in 2022, is an Fc-fusion protein containing an IL-7 PEPTIKINE, which emulates the beneficial properties of IL-7, a cytokine critical to maintaining T cell response. An important feature is its avoidance of the generation of neutralizing antibodies to native IL-7. Medikine has also identified novel PEPTIKINES that activate the IL-2/15βγc receptor and is exploring their use in bispecifics with differentiated profiles, including an IL-7R and IL-2/15Rβγc dual agonist and a cell-targeted IL-2/15Rβγc attenuated agonist. Medikine is led by an accomplished team of industry veterans with decades of experience in pioneering drug discovery technology and developing immuno-oncology therapeutics. The Company intends to both advance the clinical development of its pipeline assets as well as seek partnerships to expand clinical-stage opportunities. For more information, please visit